APLS's logo.
Ticker Symbol: APLS

Apellis Pharmaceuticals Inc

$47.11 - 07-10-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001492422

Company Profile

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 100 5th Avenue
CEO: Cedric Francois
Tags:
  • Distribution Services
  • Medical Distributors
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $46.40
Change: $0.22 ( 0.48%)
Days Range: $46.07 - $47.97
Beta: 0.65
52wk. High: $94.75
52wk. Low: $19.82
Ytd. Change -9.79%
50 Day Moving Average: $43.36
200 Day Moving Average: $62.42
Shares Outstanding: 117737289

Valuation

Market Cap: 546.3B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A